ValiRx

• 25/04/13

  New Patent Granted

• 22/04/13

  Result of AGM

• 02/04/13

  Update on Developmental and Clinical Activity

• 28/03/13

  Final Results

• 23/01/13

  Appointment of Medical Monitoring Officer

• 

  25/04/13

  ValiRx granted patent in Australia for top compound

• 

  19/04/13

  ValiRx taking huge strides in developing breakthrough cancer drug

  ValiRx is an interesting example of where the changing industry backdrop may eventually aid the smaller company. However, talk of deals with industry players is a little premature for the group, whose challenge currently is to take its lead drug candidate, VAL201 for cancer, from the pre-clinical phase into first-in-man trials.

• 

  02/04/13

  ValiRx given international showcase at prestigious American cancer event

• 

  28/03/13

  ValiRx hopes to achieve some "momentous milestones"

• 

  21/02/13

  ValiRx appoints chief commercial officer

• 

  23/01/13

  ValiRx appoints experienced medical monitoring officer for VAL201

• 

  22/11/12

  ValiRx gears up for phase I clinical trials after £2 mln cash injection

  Life sciences group ValiRx said the recent £2.03 mln cash call allows it to take VAL201 through first human clinical trials. It is hoped this potentially breakthrough treatment for cancer can tackle a number of strands of the disease including breast, ovarian and prostate forms.

• 

  01/11/12

  ValirX to raise £2.03 million to take VAL201 through first clinical trial

• 

  11/10/12

  ValiRx deal allows co to concentrate on drug development

• 

  20/09/12

  ValiRx mulls phase one trial for lead compound without partner

• 

  26/04/2013

  Stocktube video - ValiRx well-positioned to feed Big Pharma

  Dr Satu Vainikka, CEO of ValiRx (LON:VAL), tells Proactiveinvestors that good clinical progress is being made with VAL201, the company's prostate cancer drug. The company's cash position is good, and the board has been strengthened by the recent appointment of some heavy hitters in in the pharmaceutical world. Satu says the association with specialists in the area of drug development has helped considerably in taking its drug portfolio on into the clinical phase, while the presence on the board of respected industry professionals strengthens the company's proposition when it goes to talk to the big beasts of the sector, many of which are cutting back on research & development. "Big pharma is very desperate a pipeline of new development; new drugs, new therapeutic treatment," Satu notes.

• 

  25/04/13

  Thursday's most followed including Magnolia Petroleum, Taylor Wimpey, Orogen Gold and Genel Energy
• 

  02/04/13

  Dow breaks new ground; Footsie boosted by Vodafone bid talk
• 

  02/04/13

  Vodafone boosts FTSE 100 with bid buzz
• 

  02/04/13

  Tuesday's most followed: including Vodafone, Bowleven, Max Petroleum, ValliRX and Rangers FC
• 

  02/04/13

  Market Movers: Sefton Resources, Rurelec, ValiRx, Max Petroleum, Ariana Resources, Iofina, Biome Technologies

• 02/02/12

  +0.13 +0.68

  Press: ValiRx rose on news its cancer screening test biomarker (NAV3) had recently received approval by the European patent office. Source - Financial Times

  Press: ValiRx rose on news its cancer screening test biomarker (NAV3) had recently received approval by the European patent office. Source - Financial Times
• 15/12/11

  +0.02 +0.46

  Press: ValiRx rose on news that its ?gene-silencing? technology has received patent approval in Canada. It already has patents for the US,... read more

  Press: ValiRx rose on news that its ?gene-silencing? technology has received patent approval in Canada. It already has patents for the US, Europe and Australia. Source - Mail
• 16/02/11

  Press: 16.02.11: -0.52, (0.73) Press: ValiRx fell after raising GBP3.3m before expenses with a sale of new shares at 0.6p to fund the... read more

  Press: 16.02.11: -0.52, (0.73) Press: ValiRx fell after raising GBP3.3m before expenses with a sale of new shares at 0.6p to fund the development of an experimental prostate cancer treatment and a compound that aids chemotherapy.Source - Financial Times
• 14/02/11

  +1.14 +1.68

  Press: Valirx rose after announcing the UK launch of its Chlamydia SELFCheck 'over the counter' health screening product. The self diagnostic... read more

  Press: Valirx rose after announcing the UK launch of its Chlamydia SELFCheck 'over the counter' health screening product. The self diagnostic kits/packs, for women, will be sold over the counter and will provide a a definitive result within ten minutes. Source - Mail
• 25/05/10

  Press: 25.05.10: .-5, (.4) an article in the Times reports: ValiRx rose 0.07p to 0.45p after the group did a deal to sell a chlamydia... read more

  Press: 25.05.10: .-5, (.4) an article in the Times reports: ValiRx rose 0.07p to 0.45p after the group did a deal to sell a chlamydia self-testing kit in Britain and Ireland. The product, which will be marketed under the group?s SELFCheck brand, is for use at home or at sexually transmitted disease clinics. It hopes to use money from sales to fund its development work.

Valirx wants to make a structural change in science, namely to engineer a scientific breakthrough into human health and wellbeing, through early detection of disease and therapeutic intervention. Research shows that there is a high demand for new personalised medicines and services that enhance patient care, achieve faster diagnoses, and substantially improve treatment outcomes cost effectively.

Valirx is a growing company with a clear business model. We reduce risk in new product development through a rigorous clinical and commercial due diligence process, selecting drug candidates and technologies with evidence-based potential to address the unmet needs of the market. We aim to maximise returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Valirx management team is a mixture of entrepreneurial scientists and business professionals, all with experience in developing medical life science companies. The team is also experienced at transferring technologies and products into the commercial arena to generate revenue and grow shareholder value.

Our Products & Technologies

We operate through the following divisional companies:

ValiMedix is the sales and distribution division of Valirx

ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, Valirx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund the development of the GeneICE products through preclinical stages in cancer treatments.

We are also pleased to report that a further late preclinical study into the development of another of our lead therapeutics, VAL201, carried out in collaboration with Oxford University, has firmly established a potentially important role for VAL201 in treating hormone induced refractory prostate cancer and other conditions of hormone induced uncontrolled cell growth including breast and ovarian cancer, among others. These conditions currently have high medical needs.  Following the successful completion of this study, both Valirx and Oxford University now look forward to continuing the next stage of VAL201’s preclinical programme to support the regulatory requirements prior to entering clinical trials.

Our Business Divisions

We operate through the following divisional companies:

ValiPharma is a biopharmaceutical company focused on developing personalised medicines to bring more advanced therapeutic options for the treatment of cancer. For many years the Company has progressively exploited its proprietary epigenomic technology, which has led to the discovery of promising therapeutics that may prove in clinical trials to combat cancer safely and more effectively than currently used chemotherapeutics, which act indiscriminately, attacking the whole body and causing irreparable damage to normal cellular processes. Currently, ValiPharma has two lead drug candidates in late stage pre-clinical development for three indications – androgen independent prostate cancer, hormone refractory prostate cancer, and endometriosis.

ValiFinn’s specialist competency lies in epigenomics, a rapidly advancing field that enables pairing a prognostic and/or predictive biomarker with a targeted drug. This is a key part of personalised medicine, particularly in cancer patients. The Company is actively discovering, developing, and validating functional biomarkers with high specificity and sensitivity from its 5 families of patents and patent applications and related intellectual property. These are diagnostic markers of inhibition of signalling pathways, which are target sites for novel drugs to treat cancer, and predictive markers of disease progression

ValiMedix is the sales and distribution division of Valirx. The Company was established in 2009 to exploit the growing “well being” market through the marketing and distribution of reagent-based home screening tests under the brand SELFCheck. These tests are designed to have high sensitivity and specificity to detect levels or the presence of a range of biological markers e.g. PSA – prostate specific antigen; FSH – follicle stimulating hormone; H Pylori antibodies, that may be indicators of disease.

Mr Nicholas Thorniley - Chairman

Nicholas first worked in the City for Montagu Loebl and Stanley, becoming a partner in 1974. Whilst there he was a founder member of the London Oil Analysts Group and became Chairman in 1983. He joined L Messel & Co in 1981 as a partner and moved to Panmure Gordon in 1991 as a director and finally joining Investec Securities as a Director and Head of Corporate Broking in 2002. His career in the City spans some 37 years during which he moved from research to sales and on to corporate broking, where he specialised in the small mid cap area. (Member of Remuneration Committee)

Dr Satu Vainikka - Chief Executive Officer

Satu Vainikka has extensive experience in the biotechnology industry, technology commercialisation, equity financing and business management. Prior to her current role as a CEO of ValiRx, she was a founder, director and CEO of Cronos. In her past roles, Dr Vainikka has successfully developed business strategies, negotiated corporate and academic transactions and raised funding for companies. (Member of Remuneration Committee)

Mr Gerry Desler - Chief Financial Officer

Gerry Desler is a chartered accountant, who qualified in 1968 with a City firm, becoming partner in 1970. From 1985 to 1990 he was the Senior Partner. During his time in the City he specialised in consultancy work, much of it involving funding and venture capital. He was involved in one of the first joint ventures in what was then the People's Republic of China in 1980. Gerry Desler is also the Finance Director of Premier Management Holdings plc, an AIM listed company and Babble Group plc and Venture Six plc, both Plus Market listed companies. (Member of Audit Committee)

Mr Kevin Alexander - Non-Executive Director

Kevin Alexander is a solicitor and qualified as a member of the New York Bar and spent over 25 years practising law with major law firms in London and in the United States. Since leaving full time legal partnership, he has been involved with various business interests, both in the energy sector and in private equity. (Member of Environmental Committee)

Dr George Morris - Non-Executive Director

George Morris has over 20 years experience in biological and medical research and financial services. In the past, he has been a CEO, an executive, director and founder of several life sciences companies and a consultant to financial services companies. For the majority of his career he has worked in academic and commercial scientific research. He is an author numerous and an inventor on multiple patents. (Member of IT and Audit Committee)

Mr Oliver de Giorgio-Miller - Non-Executive Director

Oliver has a wealth of experience in the management and commercial advancement of life science companies. He has worked for over 30 years with several global pharmaceutical and medical device companies including Schering AG, Hoffman la Roche, Intavent-Orthofix and Photo Therapeutics, a Cancer Research UK company and he has extensive experience advising a number of other early stage biopharmaceutical and medical device companies.

ValiRx plc is a company incorporated in the United Kingdom under the Companies Act 1985, its principle place of business is in the United Kingdom.

The Total Number of shares with nominal value 0.1p in issue is 1,711,184,409. The percentage of securities not in public hands is approximately 5%. The shareholders who hold more than 3% are as follows:

The information below was last updated on 04 December 2012.

Information taken from Valirx plc website 27.03.2013